One scan at a time, QyScore® has the potential to revolutionize the treatment of CNS disease and create the potential for earlier precision on the frontlines of CNS disease.
QyScore® is a groundbreaking neuroimaging analysis platform for both clinical routine and clinical trial settings.
is a game changer.
Powered by robust technology, our platform produces a wide range of automated measures of neuroinflammation and neurodegeneration, such as whole brain, white matter, grey matter by lobe, cerebellum, white matter abnormalities and brain substructures. To facilitate review by physicians, an automated patient report is rapidly generated after each QyScore® analysis and results are viewable in our proprietary and integrated 3D visualization platform.
QyScore® decreases image reading variability and segmentation errors by 89% and has demonstrated better performance compared to certain other state-of-the-art automated methods on the market, promising precision and accuracy.
Peace of mind for routine and research by providing results you can trust.
QyScore® gives clinicians the potential to offer more accurate diagnosis and monitoring for patients, and the potential to bring enhanced trial design, improved patient selection, and endpoint protection to clinical trials. Our platform is cloud-based, easy to use and scales to fit your patient load or trial size.
For Clinical Routine, QyScore®
has the potential to:
Support timely diagnosis
Support disease & therapy monitoring
Support tailored treatment plans
Facilitate therapeutic switching
For Clinical Trials
Potential to enhance trial design, improve patient selection and protect imaging endpoints
Automates image pre-processing, quality control and image analysis
FDA-Cleared and CE-Marked platform has the potential to support the continuum of care from drug development to post-market and long-term monitoring of therapeutic effectiveness and safety.
Alzheimers and other dementias
Parkinson’s and movement disorders
These disease areas commonly use imaging and automated measurement techniques to help better characterize patients
These disease areas are ones in which we are accumulating data for future use in clinical and research settings.
Traumatic Brain Injury
Founder & CEO | Qynapse
When someone you love is declining mentally, there’s nothing worse than not having a clear diagnosis as to why. That’s why Qynapse is on a mission to transform time to diagnosis and the accuracy for diagnosis for CNS disease.
Srinivas Peddi, MD
Radiologist & Board Member | Tower Imaging Medical Group
When you remove air from a ball, it’s hard to figure that out until it’s lost a lot of volume. But if we had a tool that would let us measure more precisely? That’s super helpful. And that’s what Qynapse provides.
Former CEO | UnitedHealthcare Specialty Benefits
Payers have developed very sophisticated systems and data sets to help their members, healthcare providers and teams make better decisions about healthcare. What Qynapse provides further enhances that decision making, resulting from the whole being greater than the sum of the parts.
Bruno Dubois, MD, PhD
Professor of Neurology | Sorbonne University, Director of the Institute of Memory and Alzheimer’s Disease (IM2A) | Pitié Salpêtrière Hospital in Paris
In light of the recent breakthrough for Alzheimer’s patients – the approval of new treatment options by the FDA, Qynapse’s vision is becoming even more critical to advance the early detection of Alzheimer’s disease and to precisely monitor the therapy efficacy and safety.
David Merrill, MD, PhD
Director | Pacific Brain Health Center Pacific Neuroscience Institute
I’m excited to use QyScore® to quantify both volumetric and white matter integrity in our patients – bringing such an important layer of precision and objectivity to inform our clinical decisions.
Marwan N. Sabbagh
MD, FAAN, CCRI
Going from a diagnostic accuracy of 66-70% to better than 90% is today the most pressing topic for the Alzheimer’s disease community. I am glad to see innovative organizations like Qynapse leading the way and contributing to transform the diagnosis of Alzheimer’s disease.
Transform your Practice.
Qyscore® is a medical device software FDA-cleared – class II and CE-marked – class IIa.
Indications for Use in the U.S. (FDA): QyScore® is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures and lesions from a set of MR images. Volumetric data may be compared to reference percentile data. QyScore® is not intended for use in clinical scenarios that require evaluation of the number of the white matter hyperintensities.
Indications for Use in Europe (CE): QyScore® is an advanced processing and visualization software for automatic labeling and volumetric quantification of segmented central nervous system structures for patients older than 18 years of age. The software is intended to be used by medical personnel or neuroimaging trained personnel to support diagnosis of central nervous system diseases.